On April 7, 2015, Trillium Therapeutics Inc. (Trillium) completed its underwritten public offering of common shares (Common Shares) and Series II non-voting convertible first preferred shares (Series II Preferred Shares) in the United States. Pursuant to the offering, Trillium sold 1,750,754 Common Shares and 1,077,605 Series II Preferred Shares in each case at a price of US$19.50 per share. The offering included 228,359 Common Shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares. The gross proceeds to Trillium from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately US$55.2 million.
Trillium was represented in Canada by Borden Ladner Gervais LLP with a team led by Jay Lefton and Manoj Pundit that included Habeeb Syed and Linda Tu (corporate and securities) and Daniel Lang (tax); and in the United States by Dorsey & Whitney LLP with a team that included Dan Miller, Peter Skrief, Morgan Helme and Kelsey Dolven (corporate and securities) and John Hollinrake (tax).Leerink Partners LLC and Cowen and Company, LLC were joint book-runners for the offering and Oppenheimer & Co. Inc. was co-manager in the offering. The underwriters were represented in the United States by Goodwin Procter LLP with a team that included Thomas Levato and Brandon Thompson and in Canada by Blake, Cassels & Graydon LLP with a team that included Joseph Garcia, Chris Hewat, Samir Murji and Karim Amlani.